Clinical Longitudinal Evaluation After Regimen Stop (CLEAR) of Dupilumab in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP).

Complete discontinuation of dupilumab after long-term disease control appears feasible in only a minority of patients and is associated with early relapse in most cases.

These findings support the concept of dupilumab as a disease-controlling rather than disease-modifying or curative therapy and favor individualized dose tapering over full cessation in severe Type 2-driven chronic rhinosinusitis with nasal polyps.